The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).
Amit Bahl
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi ; Sanofi
Research Funding - Sanofi ; Sanofi
Susan Masson
Research Funding - Sanofi
Zafar I. Malik
Honoraria - Sanofi
Alison J. Birtle
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Honoraria - Janssen Pharmaceutical ; Sanofi
Santhanam Sundar
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Robert J. Jones
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Nicholas David James
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Malcolm David Mason
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
David Bottomley
No relevant relationships to disclose
Anna Lydon
Consultant or Advisory Role - Sanofi
Simon Chowdhury
Consultant or Advisory Role - Sanofi
James Wylie
No relevant relationships to disclose
Johann Sebastian De Bono
Honoraria - Sanofi